Researchers led by Université de Montréal pathology and cell-biology professor Marc Therrien have identified major structural ...

Many cancers harbor pro-proliferative mutations of the mitogen-activated protein kinase (MAPK) pathway. In BRAF-driven melanoma cells treated with BRAF inhibitors, subpopulations of cells escape ...

As of the cut-off date of April 2, 2025, a total of 21 patients had been enrolled and received at least one dose of PAS-004 in six cohorts (Capsules: 2mg, 4mg, 8mg, 15mg, 22mg / Tablets: 4mg). The ...

The results demonstrate that compared to avutometinib alone, the FAK inhibitor/avutometinib combination inhibits RAS/MAPK pathway signaling more deeply while also blocking key adaptive resistance ...

Genetic ablation or protein degradation of SHOC2 can sensitize RAS-driven cells to RAS/MAPK pathway inhibitors and prevent adaptive resistance. Identified two lead series that bind selectively to ...

Both ERAS-4001 and potential best-in-class pan-RAS molecular glue ERAS-0015 received IND clearance in May ahead of company guidance. Initial Phase 1 monotherapy data for both RAS- ...

PAS-004 has a long half-life and steady-state pharmacokinetics, potentially offering advantages over existing MEK inhibitors for NF1-mutated cancers. Enrollment and initial dosing of PAS-004 at 30 ...

(C) PFS and (D) OS in class 2 versus other MAP2K1 mutant tumors in patients treated with MEK inhibitor–containing ... mutations may be sensitive to MAPK TT, however, only when the universally ...

Accordingly, combined inhibition of PIKfyve and either the ERK-MAPK pathway or RAS itself showed robust growth suppression across a panel of KRAS-mutant PDAC models. Growth suppression was due, in ...

"Even though PIKfyve inhibitors have cleared phase 1 clinical ... The team demonstrated that tumor cells make new fat through the KRAS-MAPK pathway. "KRAS is the master regulator of pancreatic ...